IMUC - ImmunoCellular Thera...

Discounted Cash Flow Model Levered of ImmunoCellular Therapeutics, Ltd.(IMUC), Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the developme

ImmunoCellular Therapeutics, Ltd.

IMUC

PNK

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

0.198 USD

0.0214 (10.81%)

Overview Profile Financial Statements Financial Ratios Chart Analysis News Corporate Actions DCF

FMP

Home Terms of Service Privacy Policy Blog Contact Us

API

Documentation Pricing Formulas Market Indexes

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.